CD274 and neoplasm: The biological basis for this combination relies on the fact that the inhibition of the CTLA-4 pathway produces a proliferation of CD8+ cells in the lymph nodes and in the tumor tissue that is critical to stimulate the immune response mediated by anti-PDL-1/PD-1 antibodies [63,64].